Chonluten
Glu-Asp-Gly (EDG)
Chonluten is a short synthetic tripeptide with experimental cell-culture data.
Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.
Research areas
Evidence matrix
- Molecular identity
- Confirmed
The cited primary study defines the Chonluten it tested as the tripeptide Glu-Asp-Gly. This does not confirm extract products or commercial lots without analytical testing.
- Human research
- None
- Replication
- Single research group
- Clinical endpoints
- No clinical endpoints
- Safety
- Not adequately studied
- Approval
- No documented approval
The dimensions are presented separately and are not combined into an overall score.
What the source shows
The models were THP-1 monocytes/macrophages and activated endothelial cells, not clinical treatment of lung disease.
- Peptides regulating proliferative activity and inflammatory pathways in the monocyte/macrophage THP-1 cell lineLaboratory study2022
Avolio F et al.
Accessed:
Research gaps
- ·Human cells in a laboratory do not constitute a human trial. The study tested several peptides and included members of the originating group; independent replication is absent.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
Mechanism
The study examined inflammatory signaling, cytokine expression and proliferative activity in cultured cells.
- Peptides regulating proliferative activity and inflammatory pathways in the monocyte/macrophage THP-1 cell lineLaboratory study2022
Avolio F et al.
Accessed:
Study protocols
No sufficiently supported, exactly citable study protocols are available.
Calculator
Arithmetic based only on your entries. Not a dose or use recommendation.
Reported adverse effects
- ·Evidence is insufficient; absence of data is not evidence of safety. Human exposure, pharmacokinetics, toxicology, contraindications and interactions have not been adequately studied.
Contraindications and warnings
No reviewed information on this point has been recorded here yet. This does not mean there are no risks or contraindications.
Interactions
No reviewed information on this point has been recorded here yet. This does not mean there are no risks or contraindications.
Research gaps
- ·Human cells in a laboratory do not constitute a human trial. The study tested several peptides and included members of the originating group; independent replication is absent.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
- Peptides regulating proliferative activity and inflammatory pathways in the monocyte/macrophage THP-1 cell lineLaboratory study2022
Avolio F et al.
Accessed:
Sources
Sources checked: · Version 3
- Peptides regulating proliferative activity and inflammatory pathways in the monocyte/macrophage THP-1 cell lineLaboratory study2022
Avolio F et al.
Accessed: